Aleksejs Isakovs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aleksejs Isakovs has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Linda Gailite
Scientific Laboratory of Molecular Genetics, Riga Stradins University, Riga, Latvia
2 shared publications - Agnese Ušacka
Department of Health Psychology and Paedagogy, Riga Stradins University, LV-1007 Riga, Latvia
1 shared publication - Ainārs Stepens
Institute of Public Health, Riga Stradins University, Dzirciema iela 16, LV-1007 Riga, Latvia
1 shared publication - Ardis Platkājis
Department of Radiology, Faculty of Medicine, Rīgas Stradiņa Universitāte (RSU), LV-1007 Rīga, Latvia
1 shared publication - Gustavs Jānis Bērziņš
Department of Radiology, Riga Stradins University, Dzirciema Street 16, LV-1007 Rīga, Latvia
1 shared publication - Gvido Karlis Skuburs
Department of Radiology, Riga Stradins University, Dzirciema Street 16, LV-1007 Rīga, Latvia
1 shared publication
Latest Publications
- Open Access
- 28 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (15) , 2366
A Quantitative Assessment of MRI-Visible Perivascular-Space Burden Across the Cognitive Spectrum: Associations with APOE ε4 Status and Venous Sinus Volume
Background/Objectives: Perivascular spaces (PVS) are MRI-visible compartments surrounding cerebral vessels and are increasingly interpreted as markers of cerebral small-vessel disease and glymphatic-system dysfunction. PVS burden is multifactorial, with possible contributions from vascular risk, atrophy, white matter disease, sleep, inflammation, diabetes, pathological protein deposition, genetic susceptibility, and venous drainage anatomy. This study evaluated whether apolipoprotein E (APOE) ε4 carrier status and venous sinus volumes are associated with quantitative PVS burden in patients across the cognitive spectrum. Methods: In this cross-sectional observational MRI study, 110 participants with normal cognition or varying cognitive impairment underwent 3T brain MRI and cognitive assessment. PVS lesion count and total PVS volume were quantified from T2-weighted (T2W) imaging using an automated deep learning segmentation approach. Venous sinus volumes were derived for the transverse, straight, and superior sagittal sinus segments and reported in mm3. APOE genotype was analyzed as ε4 carrier status. Non-parametric correlations, ordered cognitive-stage trend tests, APOE group comparisons, and adjusted partial Spearman analyses were performed. Results: Dorsal superior sagittal sinus (SSS-D) volume was associated with PVS count (ρ = 0.353, p < 0.001) and total PVS volume (ρ = 0.285, p = 0.009). These associations persisted after adjustment for age, sex, medial temporal atrophy (MTA), Fazekas score, and estimated intracranial volume (eTIV). APOE ε4 carrier status was not associated with PVS volume or count. PVS burden tended to decrease with greater cognitive-stage severity, while MTA increased across cognitive stages. Conclusions: In this cohort, SSS-D volume was associated with automated 3T T2W MRI-detectable PVS burden, whereas APOE ε4 carrier status was not a dominant predictor. These findings support further study of venous sinus morphology as a potential contributor to MRI-visible PVS burden, while longitudinal and flow-sensitive studies are needed to clarify causality and glymphatic clearance mechanisms.
- 28 July 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (15) , 2366
Open AccessA Quantitative Assessment of MRI-Visible Perivascular-Space Burden Across the Cognitive Spectrum: Associations with APOE ε4 Status and Venous Sinus Volume
Background/Objectives: Perivascular spaces (PVS) are MRI-visible compartments surrounding cerebral vessels and are increasingly interpreted as markers of cerebral small-vessel disease and glymphatic-system dysfunction. PVS burden is multifactorial, with possible contributions from vascular risk, atrophy, white matter disease, sleep, inflammation, diabetes, pathological protein deposition, genetic susceptibility, and venous drainage anatomy. This study evaluated whether apolipoprotein E (APOE) ε4 carrier status and venous sinus volumes are associated with quantitative PVS burden in patients across the cognitive spectrum. Methods: In this cross-sectional observational MRI study, 110 participants with normal cognition or varying cognitive impairment underwent 3T brain MRI and cognitive assessment. PVS lesion count and total PVS volume were quantified from T2-weighted (T2W) imaging using an automated deep learning segmentation approach. Venous sinus volumes were derived for the transverse, straight, and superior sagittal sinus segments and reported in mm3. APOE genotype was analyzed as ε4 carrier status. Non-parametric correlations, ordered cognitive-stage trend tests, APOE group comparisons, and adjusted partial Spearman analyses were performed. Results: Dorsal superior sagittal sinus (SSS-D) volume was associated with PVS count (ρ = 0.353, p < 0.001) and total PVS volume (ρ = 0.285, p = 0.009). These associations persisted after adjustment for age, sex, medial temporal atrophy (MTA), Fazekas score, and estimated intracranial volume (eTIV). APOE ε4 carrier status was not associated with PVS volume or count. PVS burden tended to decrease with greater cognitive-stage severity, while MTA increased across cognitive stages. Conclusions: In this cohort, SSS-D volume was associated with automated 3T T2W MRI-detectable PVS burden, whereas APOE ε4 carrier status was not a dominant predictor. These findings support further study of venous sinus morphology as a potential contributor to MRI-visible PVS burden, while longitudinal and flow-sensitive studies are needed to clarify causality and glymphatic clearance mechanisms.
- Open Access
- 14 February 2022
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 8 (1) , 15
New-Born Screening for Spinal Muscular Atrophy: Results of a Latvian Pilot Study
New disease-modifying treatments have recently been approved for 5q spinal muscular atrophy (SMA) and early treatment has been associated with a better clinical outcome. Accordingly, new-born screening (NBS) for SMA should be implemented to ensure early diagnosis of affected individuals. The aim of this study was to determine the feasibility and usefulness of NBS for SMA in Latvia. Between February and November of 2021, 10,411 parents consented to participation in the study. DNA testing for the SMN1 exon 7 homozygous deletion was conducted using qPCR with fluorescent locked nucleic acid primers. In the first month of testing, reporting of results took up to a maximum of 17 days after samples arrived in the laboratory. However, following familiarisation with the procedure, the median report time was reduced to 11 days after birth. Forty cases required samples to be taken again due to poor quality of the isolated DNA transpiring from either the quality of the blood punch or manual mistakes during DNA isolation. The SMN1 exon 7 homozygous deletion was identified in two individuals, which was subsequently confirmed by multiplex ligation-dependent probe amplification. When a NBS sample is taken 48 to 72 h after birth and transported to the laboratory within two working days after collection according to legal requirements, DNA test results can be reported to healthcare professionals before the 12th day of life. Expansion of our SMA 5q NBS procedure to the whole of Latvia is feasible and would facilitate early diagnosis and result in more effective treatment. We strongly advocate that SMA is added to the national Latvia Recommended Uniform Screening Panel.
- 14 February 2022
- Published by MDPI AG in International Journal of Neonatal Screening
- Vol. 8 (1) , 15
Open AccessNew-Born Screening for Spinal Muscular Atrophy: Results of a Latvian Pilot Study
New disease-modifying treatments have recently been approved for 5q spinal muscular atrophy (SMA) and early treatment has been associated with a better clinical outcome. Accordingly, new-born screening (NBS) for SMA should be implemented to ensure early diagnosis of affected individuals. The aim of this study was to determine the feasibility and usefulness of NBS for SMA in Latvia. Between February and November of 2021, 10,411 parents consented to participation in the study. DNA testing for the SMN1 exon 7 homozygous deletion was conducted using qPCR with fluorescent locked nucleic acid primers. In the first month of testing, reporting of results took up to a maximum of 17 days after samples arrived in the laboratory. However, following familiarisation with the procedure, the median report time was reduced to 11 days after birth. Forty cases required samples to be taken again due to poor quality of the isolated DNA transpiring from either the quality of the blood punch or manual mistakes during DNA isolation. The SMN1 exon 7 homozygous deletion was identified in two individuals, which was subsequently confirmed by multiplex ligation-dependent probe amplification. When a NBS sample is taken 48 to 72 h after birth and transported to the laboratory within two working days after collection according to legal requirements, DNA test results can be reported to healthcare professionals before the 12th day of life. Expansion of our SMA 5q NBS procedure to the whole of Latvia is feasible and would facilitate early diagnosis and result in more effective treatment. We strongly advocate that SMA is added to the national Latvia Recommended Uniform Screening Panel.